Lapatinib is an orally administered small molecule that inhibits the tyrosine kinase components of the HER1 (ErbB1 or EGFR) and HER2 (ErbB2) receptors. Stimulation of HER1 and HER2 is associated with cell proliferation and with multiple processes involved in tumour progression, invasion and metastases. Overexpression of these receptors has been reported in a variety of human tumours and is associated with poor prognosis and reduced overall survival.1
Lapatinib was first approved for use in combination with capecitabine in the metastatic setting in 2007 and is currently approved in 107 countries including the U.S., Europe, Australia, India, Brazil, Russia, Turkey, South Korea and other countries around the world.
Lapatinib plus trastuzumab is approved for use in countries in the EU, Philippines, Russia and Thailand only.
Copyright 1995 - 2010 . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc)
published in this site belongs to China Daily Information Co (CDIC).
Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
